Drug Interaction:
HMG-COA reductase inhibitors include- Fluvastatin, Lovastatin, Pravastatin, Simvastatin
Refer - Lovastatin
Bile salts with Pravastatin decrease a 40% decrease in pravastatin bioavailability may occur. Take Pravastatin 1 hour before and 4 hour after bile acid sequestrant
Concomittant administration with cholestyramine or colestipol may result in approximately 40 to 50 % decrease in the mean AUC of parvastatin
Pravastatin when administered along with gemifibrol decreases the urinary excretion and protein binding of pravastatin
Indication:
Approved by FDA in October 1991
LIST OF DRUGS DURING 2006
Sr.No- 101
Name of the Drug- Pravastatin 40mg tablet (addl.stgth) Pharmacological Classification- as approved
Date of Approval- 10-08-2006
Approved by U.S.FDA on 30-12-2006 (Ref- FDA approved List)
Primary Hypercholesterolaemia
HMG-COA reductase inhibitors include- Fluvastatin, Lovastatin, Pravastatin, Simvastatin
Refer - Lovastatin
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Pravastatin cardiovascular Bristol-Meyer Squibb 20-10-2005
Approved by FDA in October 1991
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Pravastatin Lipid lowering agent 2-12-2000
2.Pravastain 40mg tablet As approved 10-08-2006
Addl.Stgth
HMG-COA reductase inhibitors include- Fluvastatin, Lovastatin, Pravastatin, Simvastatin
Refer - Lovastatin
Adverse Reaction:
Myopathy, headache, Non-cardiac chest pain, Nausea, vomiting, Diarrhea, fatigue, Biochemical abnormalities of liver function, and transcient elevation of creatinine phosphokinase, values
Contra-Indications:
Active liver disease,. Patients with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors Pregnancy and breast feeding. Women of child bearing potential unless protected by adequate contraception. hypersensitivity to the drug.
Special prercautions:
Not recommended for administration to nursing mothers. To be administered to women of child bearing age only if the patients are receving contraceptive therapy. Past history of liver disease.
Heavy alcohol ingestion Sporadic elevation of creatinine phosphokinase (CPK ) have been observed.
Dosages/ Overdosage Etc:
Approved by FDA in October 1991
Primary Hypercholesterolaemia
Dosage:
Individualise dose Initial- 10 to 20mg once daily at bed time Elderly- 10mg once daily at bed time Dosage range- 10 to 40mg once daily at bed time
Other Information:
For Availability/supplies
Contact -
1.Indian Drug Manufacturers Association (IDMA)
Phone- 022- 24944624/ 24974308
Fax- 022- 24950723
Email- idma@vsnl.com
Website: www.idma-assn.org
2.Bulk Drug Manufacturers Association (India)(BDMA)
Phone - 040-23703910/ 23706718
Fax- 040-23704804
Email- info@bdmai.org
Website: www.info@bdmai.org
Patient Information:
1. May cause photosentivity (sensitivity to sunlight) . Avoid prolonged exposure to the sun and other ultraviolet light.
2. Use sunscreens and wear protective clothing until tolerance is determined
3. Promptly report unexplained muscle pain, tenderness or weakness, especially if accompanied by fever or malaise
4. Follow dietary recommendations.
5. Take lovastatin with meals, fluvastatin and simvastatin may be taken without regrads to meals.
Pharmacology/ Pharmacokinetics:
Pharmacology:
Pravastatin inhibits 3-hydroxyl-3-methlglutaryl-coenzyme. A HMG-CoA reductase , the enzyme which catalyses the rate limiting step within the cholestreol biosynthetic pathway. By inhibiting (de novo ) chloesterol production and reducing intracellular cholesterol stores, pravastatin stimulates the synthesis and activity of low density lipoprotein(LDL) receptors, thereby enhancing the clearance of arthogenic LDL- chlolesterol
Pharmacokinetics:
Pravastatin is administered as the sodium salt. It is rapidly absorbed with the mean peak plasma concentration occuring occuring between 0.9 and 1.6hours after single or multiple dose administration in hypercholesterolamic patients. The drug has an oral bioavailability of 17%. Approximately 50% of the drug is bound to plasma proteins. It is rapidly excreted and has a terminal plasma elimination of half-life of 1.3 to 2.6 hours. Approximately 70% and 20% of the oral dose is eliminated in feces and urine, over 96 hours.
Interaction with Food:
May be taken without regards to meals.
Pregnancy and lactation:
Not recommended for nursing mothers. Women of child bearing potential should receive effective contraceptive therapy